Article Contents ::
- 1 The Brand Name PT-PRESS Has Generic Salt :: Calcitriol
- 2 PT-PRESS Is From Company Unisearch Priced :: Rs. 95
- 3 PT-PRESS have Calcitriol is comes under Sub class Drugs affecting Bone Metabolism of Main Class Endocrine,Steroid Hormones , Metabolic System
- 4 Main Medicine Class:: Endocrine,Steroid Hormones , Metabolic System Sub Medicine Class :: Drugs affecting Bone Metabolism
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name PT-PRESS Has Generic Salt :: Calcitriol
PT-PRESS Is From Company Unisearch Priced :: Rs. 95
PT-PRESS have Calcitriol is comes under Sub class Drugs affecting Bone Metabolism of Main Class Endocrine,Steroid Hormones , Metabolic System
Main Medicine Class:: Endocrine,Steroid Hormones , Metabolic System Sub Medicine Class :: Drugs affecting Bone Metabolism
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
Indications for Drugs ::
Osteoporosis, Hypoparathyroidism, Hypocalcaemia, Osteomalacia rickets, Renal osteodystrophy, Chronic kidney dialysis.
Drug Dose ::
Adult: Capsule: The optimal daily dose of Calcitriol must be carefully determined for each patient on the basis of the serum calcium level. Calcitriol can be administered orally either 0.25 mcg or 0.50 mcg. Postmenopausal osteoporosis The recommended dosage is 0.25 mcg twice daily or 0.50 mcg once daily. Serum creatinine levels should be determined at 4 weeks, 3 and 6 months and 6 monthly intervals thereafter. Renal osteodystrophy (Dialysis patients) The recommended initial dose of Calcitriol is 0.25 mcg/day. Patients with normal or only slightly reduced serum calcium levels may respond to Calcitriol doses of 0.25 mcg every other day. Most patients undergoing hemodialysis respond to doses between 0.5 and 1 mcg/day. Hypoparathyroidism & Rickets The recommended initial dosage of Calcitriol is 0.25 mcg/day given in the morning. If a satisfactory response is not observed, the dose may be increased at 2 to 4 week intervals. Predialysis patients: The recommended initial dosage of Calcitriol is 0.25 mcg/day in adults and pediatric patients 3 years of age and older. This dosage may be increased if necessary to 0.5 mcg/day. Child dose: 1 month – 3 years of age, the recommended initial dosage of Calcitriol is 10 to 15 ng/kg/day. Injection The recommended intravenous initial dose of Calcitriol injection, depending on the severity of the hypocalcemia and/or secondary hyperparathyroidism, is 1 mcg (0.02 mcg/kg) to 2 mcg administered three times weekly, approximately every other day. Doses as small as 0.5 mcg and as large as 4 mcg three times weekly have been used as an initial dose. If a satisfactory response is not observed, the dose may be increased by 0.5 to 1 mcg at two to four week intervals.
Hypercalcaemia; evidence of vitamin D toxicity. Pregnancy (dose exceeding RDA). Lactation.
Drug Precautions ::
Idiopathic hypercalcaemia. Pediatric doses must be individualised and monitored under close medical supervision. Coronary disease, renal function impairment and arteriosclerosis, especially in the elderly. Hypoparathyroidism. Excessive dosage of Calcitriol induces hypercalcemia and in some instances hypercalciuria; therefore, early in treatment during dosage adjustment, serum calcium should be determined twice weekly. Patients with normal renal function who are taking Calcitriol should avoid dehydration. Adequate fluid intake should be maintained.
Drug Side Effects ::
Adverse events associated with Calcitriol therapy are similar to those encountered with excess vitamin D intake, i.e. hypercalcemia syndrome, or calcium intoxication. Occasional acute symptoms include anorexia, headache, nausea, vomiting, abdominal pain or stomach ache and constipation.
Pregnancy category ::
Drug Mode of Action ::
Calcitriol promotes calcium absorption in the intestines and retention at the kidneys thus increasing serum calcium levels. It also increases renal tubule phosphate resorption consequently decreasing serum phosphatase levels, PTH levels and bone resorption..
Drug Interactions ::
Hypermagnesaemia may develop in patients on chronic renal dialysis. Hypercalcaemia in patients on digitalis may precipitate cardiac arrhythmias. Intestinal absorption of calcitriol may be reduced by cholestyramine and colestipol. Phenytoin, barbiturates may decrease the T1/2 of calcitriol. May develop hypercalcaemia with thiazide diuretics.